CTOs on the Move

Modern Health

www.joinmodernhealth.com

 
We make employer mental health benefits easily accessible. Request a demo today.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Hannah Willson
Chief Revenue Officer Profile

Similar Companies

Thermal Fisher Scientific Remel Products Inc

Thermal Fisher Scientific Remel Products Inc is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

West Dermatology

Our medical and cosmetic skin care centers have dermatologists specializing in skin cancer, eczema, acne, psoriasis, aging sun damage, and other skin diseases. Visit us online for info.

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

BlueSprig

Our mission is simple: we are focused on changing the world for children with autism. Learn more about our ABA Services.

AVAX Technologies

AVAX Technologies is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.